

Alex Rubinsteyn

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8540493/publications.pdf>

Version: 2024-02-01

16
papers

999
citations

1040056

9
h-index

1199594

12
g-index

26
all docs

26
docs citations

26
times ranked

1684
citing authors

#	ARTICLE	IF	CITATIONS
1	MHCflurry: Open-Source Class I MHC Binding Affinity Prediction. Cell Systems, 2018, 7, 129-132.e4.	6.2	311
2	Defining HLA-II Ligand Processing and Binding Rules with Mass Spectrometry Enhances Cancer Epitope Prediction. Immunity, 2019, 51, 766-779.e17.	14.3	187
3	MHCflurry 2.0: Improved Pan-Allele Prediction of MHC Class I-Presented Peptides by Incorporating Antigen Processing. Cell Systems, 2020, 11, 42-48.e7.	6.2	172
4	Using a Machine Learning Approach to Predict Outcomes after Radiosurgery for Cerebral Arteriovenous Malformations. Scientific Reports, 2016, 6, 21161.	3.3	88
5	Computational Pipeline for the PGV-001 Neoantigen Vaccine Trial. Frontiers in Immunology, 2017, 8, 1807.	4.8	57
6	Landscape and selection of vaccine epitopes in SARS-CoV-2. Genome Medicine, 2021, 13, 101.	8.2	30
7	Bioinformatic methods for cancer neoantigen prediction. Progress in Molecular Biology and Translational Science, 2019, 164, 25-60.	1.7	27
8	OpenVax: An Open-Source Computational Pipeline for Cancer Neoantigen Prediction. Methods in Molecular Biology, 2020, 2120, 147-160.	0.9	17
9	High-Throughput MHC I Ligand Prediction Using MHCflurry. Methods in Molecular Biology, 2020, 2120, 113-127.	0.9	4
10	A phase I study of the safety and immunogenicity of a multi-peptide personalized genomic vaccine in the adjuvant treatment of solid tumors and hematological malignancies.. Journal of Clinical Oncology, 2019, 37, e14307-e14307.	1.6	2
11	CTIM-17. PHASE I STUDY OF THE SAFETY AND IMMUNOGENICITY OF PERSONALIZED NEOANTIGEN VACCINES AND TUMOR TREATING FIELDS IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA. Neuro-Oncology, 2020, 22, ii36-ii36.	1.2	2
12	Abstract CT062: A Phase I study of the safety and immunogenicity of personalized mutation-derived tumor vaccine and treatment fields in patients with newly diagnosed glioblastoma. , 2019, , .		1
13	ATIM-31. PHASE I STUDY OF TUMOR TREATMENT FIELDS AND A PERSONALIZED MUTATION-DERIVED TUMOR VACCINE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA. Neuro-Oncology, 2018, 20, vi8-vi8.	1.2	0
14	Patient-Specific Mutation-Derived Tumor Antigens As Targets for Cancer Immunotherapy in Multiple Myeloma. Blood, 2015, 126, 1851-1851.	1.4	0
15	EPCO-22. IDENTIFYING NEOANTIGENS FOR A PERSONALIZED MUTATION-DERIVED GENOMIC VACCINE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA. Neuro-Oncology, 2020, 22, ii73-ii74.	1.2	0
16	289â€¦PGV-001: a phase 1 trial of a personalized neoantigen peptide vaccine for the treatment of malignancies in the adjuvant setting. , 2020, , .		0